The ISO certification entails extensive documentation and creation of standard operating procedures (SOP) to ensure quality services and products, customer satisfaction, continued improvement in processes, quality and workflow, and conformity to customer and regulatory requirements.
MILPITAS, Calif.--(BUSINESS WIRE)--Applied StemCell Inc., a global provider of gene editing and stem cell-based services, as well as a leader in molecular and cellular reference standard products for clinical diagnostics markets, is proud to receive certifications for two International Organization for Standardization (ISO) Quality Management Systems (QMS) on October 20, 2017, the ISO 9001:2015 and 13485:2016.
The ISO certification entails extensive documentation and creation of standard operating procedures (SOP) to ensure quality services and products, customer satisfaction, continued improvement in processes, quality and workflow, and conformity to customer and regulatory requirements. The certificate approves Applied StemCell, Inc., located in Milpitas, California (USA), providing gene-editing, stem cell, and reference standard products and services for life science research, preclinical, and clinical diagnostic global markets. In addition, we have also been awarded the ISO 13485 certification for consistently meeting customer and regulatory requirements for products and services related to medical devices, and specifically to our reference standard products.
“We are extremely proud of our team and their efforts to receive both the ISO 9001 and 13485 certifications. This new milestone reinforces Applied StemCell’s mission to offer high quality biotechnology services and products so that our customers can be assured that their expectations are met or exceeded,” stated Dr. Ruhong Jiang, CEO of Applied StemCell, Inc.
With this new resource, Applied StemCell looks forward to dynamically accomplish our mission to equip the research community with the best quality tools for advancing biomedical research and enabling novel and effective therapeutic solutions.
Applied StemCell’s Strategy and Pipeline
Applied StemCell’s strategy is to utilize its core strengths to expand its IP portfolio and develop a strong therapeutic pipeline based on its patented gene editing technologies. The company’s expertise in utilizing genome editing for both animal and cell model generation, as well as its portfolio of improved genome editing technologies, make it uniquely poised to develop transformative solutions to pressing medical challenges.
About Applied StemCell
Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT™ and CRISPR/Cas9. For more information, please visit www.appliedstemcell.com.
Contacts
Applied StemCell, Inc.
Maki Ogawa, 408-773-8007
Marketing Director
maki.ogawa@appliedstemcell.com
Return to list
